ISNES, Belgium, Dec. 5, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced that its Executive Vice President, Scott Powell, is scheduled to attend two conferences in December.
During the conferences, management will outline Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced two large clinical trials in colorectal cancer at the University of Copenhagen, Denmark, expected to be completed in the first half of 2018.
Details of the conferences are as follows:
|
Conference: |
LD Micro Conference Main Event X | |
|
Date: |
Wednesday, December 6, 2017 | |
|
Time: |
11:00 a.m. PST | |
|
Location: |
Luxe Sunset Hotel, Los Angeles, CA | |
|
Conference: |
Benchmark Company, LLC Micro Cap Discovery One-on-One Conference | |
|
Date: |
Thursday, December 14, 2017 | |
|
Location: |
Palmer House Hilton, Chicago, IL |
Persons attending any of the above-referenced conferences who would like to schedule a 1-on-1 meeting with Volition management during such conference may do so by contacting Joseph Green of Edison Advisors at JGreen@edisongroup.com or Scott Powell, Executive Vice President, at S.Powell@volitionrx.com.
About Volition
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
|
Louise Day, Volition +44 (0)7557 774620 |
Scott Powell, Volition +1 (646) 650 1351 |
|
Joseph Green, Edison Advisors +1 (646) 653 7030 |
Rachel Carroll, Edison Advisors +44 (0)20 3077 5711 |
SOURCE VolitionRx Ltd